Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

Study type: Clinical Trials Posting date: 08/06/2024 Last updated: 08/06/2024 Status: Recruiting Phase: Phase 2 Country: United States; Canada Eligibility:

Age 18 years or older; definitive diagnosis of AA of more than 6 months; diagnosis of severe AA, as determined by 50% or greater scalp hair loss, current episode of hair loss < 8 years, and no evidence of hair regrowth within 6 months; willingness in maintaining consistent hair style and hair care

Drug: amlitelimab Administration: subcutaneous injection Sponsor: Sanofi Sponsor Link: Click here ClinicalTrials.gov link: Click here Location: Multiple locations

Description:

For more information on this study, visit Clinicaltrials.gov or Sanofistudies.com.